GLUCAGON KIT

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

GLUCAGON (RECOMBINANT DNA ORIGIN)

可用日期:

ELI LILLY CANADA INC

ATC代码:

H04AA01

INN（国际名称）:

GLUCAGON

剂量:

1MG

药物剂型:

KIT

组成:

GLUCAGON (RECOMBINANT DNA ORIGIN) 1MG

给药途径:

INTRAMUSCULAR

每包单位数:

1 ML

处方类型:

Schedule D

治疗领域:

GLYCOGENOLYTIC AGENTS

產品總結:

Active ingredient group (AIG) number: 0142861001; AHFS:

授权状态:

CANCELLED POST MARKET

授权日期:

2023-12-18

产品特点

GLUCACON (rDNA Origin) Product Monograph
Page 1 of 32
PRODUCT MONOGRAPH
GLUCAGON
GLUCAGON FOR INJECTION, RDNA ORIGIN
1 MG GLUCAGON PER VIAL
Sterile Lyophilized Powder and Diluent
Hyperglycemic Agent
©
Eli Lilly Canada Inc.
3650 Danforth Avenue
Toronto, Ontario
M1N 2E8
1-888-545-5972
Date of Approval:
July 9, 2012
www.lilly.ca
Submission Control No: 139332
GLUCACON (rDNA Origin) Product Monograph
Page 2 of 32
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
..............................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................
3
CONTRAINDICATIONS
.........................................................................................................
4
ADVERSE REACTIONS
.........................................................................................................
6
DRUG INTERACTION
............................................................................................................
8
DOSAGE AND ADMINISTRATION
.....................................................................................
9
OVERDOSAGE
......................................................................................................................
11
ACTION AND CLINICAL PHARMACOLOGY
.................................................................. 12
STORAGE AND STABILITY
...............................................................................................
13
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................... 13
PART II: SCIENTIFIC INFORMATION
..............................................................................
14
PHARMACEUTICAL INFORMATION
...............................................................................
14
CLINICAL TRIALS
...........................................................................................................